News Releases

Summary Toggle Teligent, Inc. Announces Second Quarter 2018 Results

BUENA, N.J. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced its financial results for the second quarter ended June 30, 2018 . Second Quarter 2018 Highlights The Company adopted ASC 606: Revenue from

August 8, 2018

PDF Version
Summary Toggle Teligent, Inc. to Hold Conference Call for Second Quarter 2018 Results

BUENA, N.J. , Aug. 03, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:30pm ET on Wednesday August 8, 2018 to discuss the 2 nd quarter 2018 financial results and business

August 3, 2018

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Approval of Hydrocortisone Lotion USP, 2.5%

BUENA, N.J. , July 30, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

July 30, 2018

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Approval of Hydrocortisone Cream USP, 2.5%

BUENA, N.J. , July 24, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

July 24, 2018

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Approval of Lidocaine and Prilocaine Cream USP, 2.5%/2.5%

BUENA, N.J. , July 02, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

July 2, 2018

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Approval of Fluocinonide Gel, 0.05%

BUENA, N.J. , June 20, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

June 20, 2018

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Approval of Diflorasone Diacetate Ointment 0.05%

BUENA, N.J. , June 13, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

June 13, 2018

PDF Version
Summary Toggle Teligent, Inc. Announces Closing Of $25 Million Secured Credit Facility

BUENA, N.J. , June 05, 2018 (GLOBE NEWSWIRE) -- TELIGENT, Inc. (NASDAQ:TLGT) Teligent, Inc. (“Teligent”) announced today that it has entered into a Credit Agreement with certain funds managed by Highbridge Capital Management, LLC , an existing stakeholder, on June 1 , 2018. Pursuant to the Credit

June 5, 2018

PDF Version
Summary Toggle Teligent, Inc. Announces First Quarter 2018 Results

BUENA, N.J. , May 08, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced its financial results for the first quarter ended March 31, 2018 . First Quarter 2018 Highlights The Company adopted ASC 606: Revenue from

May 8, 2018

PDF Version
Summary Toggle Teligent, Inc. to Reschedule Conference Call for First Quarter 2018 Results

BUENA, N.J. , May 07, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, initially announced the Company would hold a conference call at 4:30pm ET on Monday, May 7, 2018 to discuss the 1 st quarter 2018 financial results and business

May 7, 2018

PDF Version